Sickle Cell Disease

Sickle Cell Disease Recent News

Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Bluebird bio Inc (NASDAQ: BLUE) 
Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment
Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced 
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
Imara Inc (NASDAQ: IMRA) has announced a 
See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use
Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies
Imara Raises $50M In Equity Funding To Support Development Of Sickle Cell Treatment Candidate
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study
GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi
Global Blood Therapeutics Inc (NASDAQ: GBT) has 
Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study
Cyclerion Therapeutics Inc (NASDAQ: CYCN) shares are pulling back sharply following a couple of clinical trial updates from the company.
Marijuana Shows Promise In Sickle Cell Disease Treatment
This article was originally published on The Fresh Toast, and appears here with permission.
GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial
Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting
Bluebird Bio's Wings Clipped, Morgan Stanley Downgrades
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
Why Have Shares Of Global Blood Therapeutics Skyrocketed Since Its Debut?

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved